Drug Discovery World

OCTOBER 16, 2023

Dr Salako says there are some clear fields of work associated with different areas, which include: Hertfordshire as a cell and gene therapy hub, with a number of companies in this space clustered around Stevenage. billion in funding.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

pharmaphorum

NOVEMBER 30, 2022

The biggest gathering of pharma companies in Europe right now on the commercial side, the Veeva Systems Summit permits the sharing of best practices and of new ideas. Facts that they gleaned included: Across Europe, only 52% of HCPs will accept a visit from a pharma company (i.e.

Life Science 97

Life Science Pharma Companies Sales Marketing 97

Delveinsight

DECEMBER 15, 2020

The FTA designation will help the pharma company to advance its research and development in the NASH landscape and help its commercialization in the market. At present, there are no approved therapies for NASH. The present NASH treatment market is dominated and supported by off-label therapies.

Vaccination 54

Vaccination Vaccine Gene Therapy Gene 54

pharmaphorum

JUNE 11, 2021

The Philadelphia-based company said it had taken the decision to go down the biologics license application (BLA) route for Covaxin based on FDA feedback to the EUA data package it had submitted to the agency. Bharat has also reported data suggesting the shot is effective against the beta (B.1.351) 1.351) variant.

Vaccination 62

Vaccination Vaccine Licensing Licensing 62

Drug Discovery World

MARCH 29, 2023

Regulatory data protection (RDP) period RDP refers to the time when generic drug makers cannot refer to an innovator drug’s data to obtain a marketing authorisation 2. According to EFPIA, RDP protects an innovator’s investment by granting a limited period of exclusivity on the data it generated, starting from marketing authorisation 4.

Clinical Trials 52

Clinical Trials Clinical Trials Production Medicine 52

pharmaphorum

SEPTEMBER 29, 2020

As of 2018, there were over 1,100 cancer therapies in development, and as of 2020, 362 of them were cell and gene therapies. The industry is asking itself how to stay innovative, how to develop and bring to market higher quality therapies to patients – and how to do this faster and more efficiently.

Research 125

Research Gene Editing Gene Development 125

pharmaphorum

SEPTEMBER 1, 2020

Previously a centre of the trade in textiles and dyes, Swiss manufacturers gradually began to realise their dyestuffs had antiseptic and other properties and began to market them as pharmaceuticals, in contrast to the origin in pharmacies of other enterprises. An advert for Bayer’s Aspirin from the early 20th century.

Medicine 145

Medicine Insulin Pharmacy Drugs 145

Drug Discovery World

AUGUST 5, 2022

Everyone can benefit from sharing experiences and learning from experts and specialists outside of their workplace or laboratory, and recruiting expert knowledge from outside of the organisation not only adds to a business’ knowledge bank but can also help to accelerate development and the speed of bringing new therapies to market.

Development 52

Development Drugs Production Gene Therapy 52

XTalks

MARCH 22, 2023

While not a record-breaking deal at $17 billion, the buyout strengthened Pfizer’s injectables business unit with the company reporting an 11 percent increase in revenue the following year. And drugmakers are using their R&D expenditure to justify setting astronomically high list prices for new therapies.

Life Science 97

Life Science Drugs FDA Approval Vaccination 97

The Pharma Data

DECEMBER 30, 2020

In short, the advisory committee did not vote to recommend the drug to the agency, which has a PDUFA date of March 7, 2021 to decide whether to approve the aducanumab Biologics License Application (BLA). market first, based on an evaluation by the independent board members. The company has a market cap of $15.4

Vaccination 52

Vaccination Vaccine Gene Therapy Trials 52

Pharmaceutical Technology

MAY 26, 2023

Enzymatic DNA production company Touchlight have augmented its DNA production capabilities with a newly announced expansion to its London facilities. Tripling its production capacity, Touchlight can now manufacture 8kg plasmid DNA, a key component for mRNA gene therapies and vaccines.

DNA 130

DNA Manufacturing Gene Therapy Gene 130